PepsiCo earnings beat estimates, but demand for drinks and snacks drops in North America

PepsiCo earnings beat estimates, but demand for drinks and snacks drops in North America


Bottles of Pepsi soda are seen on display at a Target store on February 09, 2024 in the Flatbush neighborhood of Brooklyn borough New York City.

Michael M. Santiago | Getty Images

PepsiCo reported mixed quarterly results on Tuesday as demand for its snacks and drinks fell in North America for the fifth straight quarter.

Shares of the company fell more than 1% in premarket trading.

Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

  • Earnings per share: $1.96 adjusted vs. $1.94 expected
  • Revenue: $27.78 billion vs. $27.89 billion expected

Pepsi reported fourth-quarter net income attributable to the company of $1.52 billion, or $1.11 per share, up from $1.3 billion, or 94 cents per share, a year earlier.

Excluding restructuring, impairment charges and other items, the food and beverage company earned $1.96 per share.

Net sales dropped 0.2% to $27.78 billion.

The company’s organic revenue, which excludes acquisitions, divestitures and foreign exchange, rose 2.1% in the fourth quarter.

Pepsi’s worldwide volume increased 1% for convenient foods and 1% for beverages. The metric strips out pricing and foreign exchange.

But demand was weaker in the company’s home market, North America. Pepsi has previously said that shoppers in the U.S. have grown more cautious, snacking less and making fewer purchases at convenience stores.

Frito-Lay North America’s volume fell 3% in the quarter. Consumers have been snacking less as they watch their grocery budgets, thanks to several years of higher food prices and interest rates.

“In 2024, the salty and savory snack categories underperformed broader packaged food, following multiple years in which these categories had outperformed packaged food,” CEO Ramon Laguarta and CFO Jamie Caulfield said in prepared remarks.

The company’s North American beverage unit reported a 3% decline in quarterly volume. But there were some bright spots for the division, as Gatorade gained market share and Mountain Dew Baja Blast surpassed $1 billion in annual sales.

Quaker Foods North America, still reeling from a recall from the prior December, saw its volume fall 6%. The company expects that Quaker’s performance will improve in 2025 as it laps the fallout from the recall, executives said in prepared remarks.

For 2025, Pepsi is projecting a low-single digit increase in its organic revenue and a mid-single digit increase in its core constant currency earnings per share.

“Looking ahead to 2025, we will continue to build upon the successful expansion of our international business, while also taking actions to improve performance in North America,” Laguarta said in a statement.



Source

E.l.f. Beauty posts earnings beat, raises full-year guidance
Business

E.l.f. Beauty posts earnings beat, raises full-year guidance

Elf Beauty cosmetics Courtesy: e.l.f Beauty E.l.f. Beauty reported a huge earnings beat Wednesday and raised its guidance for the fiscal year. E.l.f. stock was up as much as 15% in after-hours trading before losing the majority of those gains. Here’s what the company reported for the third fiscal quarter, compared with analyst estimates from […]

Read More
Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs
Business

Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs

NFL Hall of Famer Terrell Owens said Wednesday that the recent snubs of New England Patriots owner Robert Kraft and former coach Bill Belichick from the institution show the system is flawed, and someone needs to be held accountable. “It’s just plain dumb” Owens told CNBC Sport in an interview in San Francisco ahead of […]

Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Business

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market.  Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]

Read More